Daewoong Indonesia History
Daewoong : 20 Years of Growth with Indonesia
2020s
2010s
2000s
Daewoong :
20 Years of Growth with Indonesia
Since 2005, Daewoong has been a key partner in Indonesia’s pharmaceutical and biopharmaceutical industry. From establishing the country’s first GMP biopharmaceutical plant to launching Indonesia’s first biosimilar, Daewoong has led innovation in Indonesian healthcare. Through scholarship programs, research institutes, and social contributions, Daewoong continues to nurture local talent and expand medical access. In 2024, we obtained GMP certification for stem cell production and launched the DF Korean Center in Bali, marking a new chapter of collaboration and innovation. Daewoong remains committed to advancing healthcare and growing together with Indonesia.
the 2020s,
Present
2026.04
Secured product approval from BPOM for 'Fexuclue', a self-developed P-CAB for GERD
2025.12
Secured product approval from BPOM for 'Envlo', a self-developed SGLT-2 inhibitor for type 2 diabetes
2025.12
Launched ‘DEEP Master Course’, an aesthetic combination procedure training program for Indonesian medical professionals
2025.11
Launched dyslipidemia treatment ‘Crezet’ and initiated the ‘Lower LDL-C’ campaign
2025.11
Conducted a joint campaign with BPOM and medical professionals to eradicate illegal toxins
2025.09
Honored with the ‘2025 Best Innovation in Biotechnology Award’
2025.09
Obtained CPOB (GMP) certification for Stem Cells, NK Cells, and Exosomes at the DPI facility
2025.07
Officially launched the 'K-Aesthetic Total Solution' based on Nabota combination procedures
2025.02
Expanded collaboration with the University of Indonesia (UI) for medical device development and talent cultivation
2025.01
Pioneered the first-ever NK cell technology transfer to Indonesia and secured local production capabilities
2024.10
Established the Daewoong-ITB DDS Joint Research Center to accelerate pharmaceutical innovation and talent development
2024.09
Inaugurated the Stem Cell Plant in Cikarang, marking the start of bilateral R&D cooperation
2024.09
Daewoong Biologics obtains GMP certification for stem cell processing and production facility
2024.06
Signed an MOU with IPB University for primate research cooperation and the establishment of a research center
2024.06
The Commissioner of BPOM visited Daewoong's research center in Korea to reaffirm the strategic partnership.
2023
K-Aesthetic Clinic, ‘NULOOK’ opened NULOOK designated as the children's health management institution for the Flower of Hope Orphanage.
2022
Donation of  ‘foam dressing’ Easy Foam to earthquake victims (CGBio)

Started recruiting and nurturing excellent Indonesian talent
in the quality department (QA∙QC) at the Osong plant
2021
Master’s and Doctoral Credit Completion Scholarship Program
(Drug Delivery System) begins
2020
Launch of a scholarship program for outstanding Indonesian talent
the 2010s
2019
Health checkups for 1,000 Indonesian firefighters, spinal surgery for 100 people
2018
Established Bio Technology Research Center in University Indonesia
Conduct biopharmaceutical stability analysis and bio talent development
2017
Production of Indonesia’s first biosimilar ‘Epodion’Export of bulk API (EPO Epodion) produced by Daewoong Infion
2015
Daewoong Infion obtains GMP certification through PIC/sand on-site inspection by the Korean Ministry of Food and Drug Safety
2012
The establishment of the joint venture Daewoong Infion marks the beginning of mutual growth in earnest

Construction of Indonesia's first biopharmaceutical factory meeting cGMP standards
the 2000s
2009
Launch of a scholarship program for outstanding Indonesian talent
2005
DPCI Established in Jakarta as the Indonesian Branch